Across TCGA pan-cancer cohorts, GRK6 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated GRK6 data layer compared with 21 for mass-spec protein and 4 for mass-spec protein.
The strongest signal is observed in esophageal carcinoma (ESCA), where higher GRK6 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated GRK6 expression acts as an unfavorable survival marker.
ESCA and UCEC are the cancer types where GRK6 Mutation most reproducibly stratifies survival.